Braveheart Bio, Inc. (BRVE)
NASDAQ · N/A
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Braveheart Bio, Inc. is trading at $20.86, down 2.89% on the session. The 50 day average sits at $24.20 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 49.1, which reads as neutral, and MACD is bullish crossover. Volume is below average.
The nearest support is around $18.00 with resistance near $29.25, so that band frames the current range. Average daily movement is roughly $1.79, or about 8.6% of the share price, which is what any stop placement has to allow for. The overall health score of 37 out of 100 combines a trend score of 32, momentum of 66 and a risk score of 4.
Technical indicators
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Company website